1. Home >
  2. M&A >
  3. Divestiture >
  4. United States >
  5. Saol Therapeutics Exits Saol Therapeutics - Baclofen Franchise

Investment Summary

Saol Therapeutics Exits Saol Therapeutics - Baclofen Franchise

On January 6, 2022, invested in life science company Saol Therapeutics - Baclofen Franchise from Saol Therapeutics

Investment Highlights
  • This is transaction in the Life Science sector.
  • This is transaction in the United States.
  • This is transaction in Georgia.

Investment Summary
Date 2022-01-06
Target Saol Therapeutics - Baclofen Franchise
Sector Life Science
Sellers(s) Saol Therapeutics
Deal Type Divestiture

Target

Saol Therapeutics - Baclofen Franchise

Roswell, Georgia, United States
Saol Therapeutics' Baclofen Franchise is a pipeline product under development. Lioresal® is an intrathecal baclofen product delivered through an implantable intrathecal pump for use in the management of severe spasticity of cerebral or spinal origin for the institutional market. LYVISPAHTM is a baclofen oral granules (5, 10, and 20 mg) specialty product recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of spasticity.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Seller(S) 1

SELLER

Saol Therapeutics

Roswell, Georgia, United States
Category Company
Founded 2015
Sector Life Science
DESCRIPTION

Saol Therapeutics is a privately held specialty pharmaceutical company focused on providing therapies to patients with rare diseases. Saol Therapeutics has a strategic emphasis on the neurology therapeutic area. Saol Therapeutics was founded in 2015 and is based in Roswell, Georgia.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
State: Georgia M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2022 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-08-31 Aptevo Therapeutics - Hyperimmune Commercial Products

Seattle, Washington, United States

Aptevo Therapeutics, Inc. - Hyperimmune Commercial Products comprises WinRho SDF, HepaGam B, and VARIZIG. WinRho SDF for autoimmune platelet disorder and hemolytic disease of the newborn; HepaGam B for the prevention of Hepatitis B following liver transplantation and for treatment following hepatitis B exposure; and VARIZIG for treatment following exposure to varicella zoster virus for individuals with compromised immune systems.

Buy $75M
Mergr

Solution for

Product

Company

Legal